Managing Myeloma logo
Developments in Newly Diagnosed Multiple Myeloma:
Considerations for Improved Patient Outcomes

Thursday, June 2, 2022
12:00 pm ET – 1:00 pm ET

Register Now
Faculty

Saad Z. Usmani, MD, FACP Sagar Lonial, MD, FACP​
Chief of Myeloma Service
Department Chair​
Professor of Hematology and Medical Oncology​
Emory University School of Medicine​
Atlanta, Georgia

Webinar Begins In

Agenda

Join in on the conversation with a leading expert in multiple myeloma as he provides the latest updates in novel treatment regimens used in practice today and reviews emerging regimens currently in clinical trials for potential use in the future. As a participant, you will have the opportunity to discuss how you currently approach treatment decisions for your patients with newly diagnosed multiple myeloma (NDMM) and strategies that may be incorporated into treatment to impact patient quality of life.

Treatment Updates in Newly Diagnosed Multiple Myeloma

  • Today’s standard of care in frontline treatment regimens
  • Role of transplant eligibility in treatment decisions
  • Incorporating monoclonal antibody therapy into the treatment paradigm for both transplant-eligible and -ineligible patients
  • Dosages, new SQ formulation and supportive care considerations: best practices
  • Emerging multi-drug combinations 

The Importance of Patient-Centered Care

  • Best practices to implement shared decision-making when discussing NDMM treatment options with patients and families
  • Real-world cases; looking at the data and applying to practice
  • Sharing insights; a look at the challenges and barriers in care from medication adherence and choosing the optimum regimen, keeping in mind patient-related factors impacting overall outcomes

Interactive Question and Answer Session

Conclusion and Discussion

Program Overview
The faculty will highlight the latest updates in the upfront treatment for newly diagnosed multiple myeloma (NDMM) and provide their practical clinical insights to enhance the implementation of new findings into practice. You will have the ability to discuss cases one-on-one with a leading myeloma expert, explore how patient management is approached today, and what treatment may look like in the near future.

Target Audience
This activity is targeted to a multidisciplinary team of physicians, nurses, pharmacists and ancillary healthcare clinician team members practicing in community cancer centers.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

  • Personalize initial therapy and maintenance approaches for NDMM based on patient and disease characteristics, and the latest evidence from clinical trials and real-world experience
  • Identify the most appropriate therapies for patients with NDMM who have underlying comorbidities and who have treatment-related adverse events that necessitate changing therapeutic strategies
  • Utilize patient education and shared decision-making approaches to improve patient satisfaction and outcomes

Accreditation

MediCom Worldwide, Inc. CME Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-22-002-L01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom Worldwide, Inc. Nursing Credit
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 22-002-153

Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures
Dr. Sagar Lonial has relevant financial relationships related to advisory activities from AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation ‒ A Bristol-Myers Squibb Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Novartis AG, and Takeda Oncology. He has received research grant(s) from Bristol-Myers Squibb, Celgene, Janssen, and Takeda. He is on the board of TG Therapeutics, Inc.

Dr. Saad Usmani has relevant financial relationships related to advisory activities and consulting from Endo Pharmaceuticals Inc., Genentech, Inc., Gilead, Oncopeptides, AB, Sanofi, Seattle Genetics, Inc., SecuraBio, and TeneoBio. He has received research grant(s) from Amgen Inc., Array BioPharma, Bristol-Myers Squibb Company, Celgene Corporation - A Bristol-Myers Squibb Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Pharmacyclics, Inc., Sanofi, Seattle Genetics, Skyline Diagnostics B.V, and Takeda Oncology.

All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Instructions for Participation and Credit

There are no fees for participating in this activity.

In order to receive credit, all participants must complete the post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.

Participants will also receive a link to complete the post-test and evaluation 48 hours following the program.

CME and CNE Credit certificates will be emailed 4 weeks following receipt of completed requirements.

CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation.

If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x110 or [email protected].
Provided by
MediCom Worldwide, Inc. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.